EUROPE CANCER BIOMARKER MARKET FORECAST 2017-2025

EUROPE CANCER BIOMARKER MARKET FORECAST 2017-2025

  • August 2017 •
  • 75 pages •
  • Report ID: 5067720
KEY FINDINGS
The Europe cancer biomarker market is poised to grow at a CAGR of 13.46% for the years 2017-2025. The total income generated by the market is also predicted to increase to up to $8646 million by the end of this forecast period.

MARKET INSIGHTS
The European market has a huge opportunity to grow in personalized medication on account of the support generated for the biomarkers test, growing medical tourism, and the rising number of cancer patients in the region. Also, the various market segments and sub-segments with respect to diseases, discovery, and diagnosis are proving to be quite profitable for the market growth. However, the lack of acceptance of the cancer biomarker from the general populace, unfavorable compensation situation and a shortage of skilled personnel remains to be the major issues faced by the market.

COMPETIIVE INSIGHTS
Clarient Inc, Becton Dickinson and Company, Ambrilia Biopharma Inc, Abbott Laboratories, Roche Diagnostics Ltd, Qiagen N.V, Affymetrix Inc, etc are some of the leading players in the market.